KINASE INHIBITORS

摘要

PURPOSE: A novel protein kinase inhibitor is provided to treat cancer, autoimmune diseases, infection, cardiovascular diseases, neurodegenerative diseases. CONSTITUTION: A kinase inhibitor compound is denoted by chemical formula I. A pharmaceutical formulation contains the compound of chemical formula I with a pharmaceutically acceptable carrier, diluents, or excipient. A method for treating protein kinase-mediated diseases comprises a step of administering therapeutically effective amount of the compound of chemical formula I or pharmaceutically acceptable salt to a subject to be treated. The kinase inhibitor compound is used by intravenous, subcutaneous, colorectal, parenteral intramuscular, nasal, skin, topical, ear, oral, ocular, or sublingual administration or inhalation. A method for suppressing SYK, PYK2, FAK, ZAP70, PIM1, FLT3, RET, JAK2, JAK3, LRRK2, LRRK2(G2019S), ABL1(T315I), AURKB, AXL, FLT3, KIT, KIT(D816V), KIT(V559D,T670I), MKNK2, MLK1, PDGFRB, PLK3, RET, SNARK, SRPK3, TAK1, or TYK2 signal transduction in the subject comprises a step of administering effective amount of the compound of chemical formula I.